Cancer

Rakovina Therapeutics Announces Additional Synthesized Compounds in its AI-Driven Cancer Drug Discovery Program

VANCOUVER, British Columbia, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO), a biopharmaceutical company advancing…

11 months ago

Veru to Report Fiscal 2025 First Quarter Financial Results on February 13, 2025

MIAMI, FL, Feb. 06, 2025 (GLOBE NEWSWIRE) -- Veru Inc. (NASDAQ: VERU), a late clinical stage biopharmaceutical company focused on…

11 months ago

Cortechs.ai and EDAP Announce World’s First OnQ™ Prostate-Assisted Focal One® Robotic HIFU Procedure at UCSF Prostate Cancer Center

First Focal One® procedure utilizing Cortechs.ai’s advanced MRI-imaging technology, OnQ Prostate, successfully performed at the University of California, San Francisco…

11 months ago

Home Fitness Equipment Market to Grow by USD 4.44 Billion (2024-2028), Increased Demand for Home Fitness Equipment Boosts the Market, Report on AI-Powered Market Evolution – Technavio

NEW YORK, Feb. 6, 2025 /PRNewswire/ -- Report on how AI is driving market transformation - The global home fitness equipment…

11 months ago

Izotropic Reschedules Investor Conference Presentation to March 13th

Vancouver, British Columbia and Sacramento, California--(Newsfile Corp. - February 5, 2025) - Izotropic Corporation (CSE: IZO) (OTCQB: IZOZF) (FSE: 1R3)…

11 months ago

Volition to Host Virtual Investor Event on Nu.Q® NETs, “Casting a New Light on Sepsis Management”, on February 14, 2025

HENDERSON, Nev., Feb. 5, 2025 /PRNewswire/ -- VolitionRx Limited (NYSE AMERICAN: VNRX) ("Volition"), a multi-national epigenetics company, today announced it…

11 months ago

Nuvectis Pharma Announces Pricing of $13.5 Million Public Offering of Common Stock

FORT LEE, N.J., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Nuvectis Pharma, Inc. (Nasdaq: NVCT), a clinical-stage biopharmaceutical company focused on…

11 months ago

Counterpart Health Signs Multi-Year Agreement with Southern Illinois Healthcare

WILMINGTON, Del., Feb. 05, 2025 (GLOBE NEWSWIRE) -- Counterpart Health, Inc. (“Counterpart”), an AI-powered physician enablement platform, today announced a…

11 months ago

Myriad Genetics and Lumea Collaborate to Enhance Access to the Prolaris Biomarker and MyRisk Hereditary Cancer Tests through BxLink Integration

SALT LAKE CITY, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic and genomic…

11 months ago